Eduardo Beltrán

Eduardo Beltrán

Auto-generated profile, based on publicly available information

Eduardo Beltrán

Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MSMelania Spadaro
Melania Spadaro
SWStephan Winklmeier
Stephan Winklmeier
EBEduardo Beltrán
Eduardo Beltrán
CMCaterina Macrini
Caterina Macrini
RHRomana Höftberger
Romana Höftberger
EMEdgar Meinl
Edgar Meinl

18 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGCatharina C. Gross
Catharina C. Gross
CMCéline Meyer
Céline Meyer
UBUrvashi Bhatia
Urvashi Bhatia
LYLidia Yshii
Lidia Yshii
IKIlka Kleffner
Ilka Kleffner
RLRoland Liblau
Roland Liblau
Neuroinflammation is often associated with blood-brain-barrier dysfunction, which contributes to neurological tissue damage. Here, we reveal the pathophysiology of Susac syndrome (SuS), an enigmatic neuroinflammatory disease with central nervous system (CNS) endotheliopathy. By investigating immune cells from the blood, cerebrospinal fluid, and CNS of SuS patients, we demonstrate oligoclonal expansion of terminally differentiated activated cytotoxic CD8+T cells (CTLs). Neuropathological data derived from both SuS patients and a newly-developed transgenic mouse model recapitulating the disease indicate that CTLs adhere to CNS microvessels in distinct areas and polarize granzyme B, which most likely results in the observed endothelial cell injury and microhemorrhages. Blocking T-cell adhesion by anti-α4 integrin-intervention ameliorates the disease in the preclinical model. Similarly, disease severity decreases in four SuS patients treated with natalizumab along with other therapy. Our study identifies CD8+T-cell-mediated endotheliopathy as a key disease mechanism in SuS and highlights therapeutic opportunities.

30 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
EBEduardo Beltrán
Eduardo Beltrán
LGLisa Ann Gerdes
Lisa Ann Gerdes
JHJulia Hansen
Julia Hansen
AFAndrea Flierl-Hecht
Andrea Flierl-Hecht
SKStefan Krebs
Stefan Krebs
KDKlaus Dornmair
Klaus Dornmair
Multiple sclerosis (MS) is a disabling disease of the CNS. Inflammatory features of MS include lymphocyte accumulations in the CNS and cerebrospinal fluid (CSF). The preclinical events leading to established MS are still enigmatic. Here we compared gene expression patterns of CSF cells from MS-discordant monozygotic twin pairs. Six "healthy" co-twins, who carry a maximal familial risk for developing MS, showed subclinical neuroinflammation (SCNI) with small MRI lesions. Four of these subjects had oligoclonal bands (OCBs). By single-cell RNA sequencing of 2752 CSF cells, we identified clonally expanded CD8+ T cells, plasmablasts, and, to a lesser extent, CD4+ T cells not only from MS patients but also from subjects with SCNI. In contrast to nonexpanded T cells, clonally expanded T cells showed characteristics of activated tissue-resident memory T (TRM) cells. The TRM-like phenotype was detectable already in cells from SCNI subjects but more pronounced in cells from patients with definite MS. Expanded plasmablast clones were detected only in MS and SCNI subjects with OCBs. Our data provide evidence for very early concomitant activation of 3 components of the adaptive immune system in MS, with a notable contribution of clonally expanded TRM-like CD8+ cells.

13 March 2023 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAdrian Gottschlich
Adrian Gottschlich
MTMoritz Thomas
Moritz Thomas
RGRuth Grünmeier
Ruth Grünmeier
SLStefanie Lesch
Stefanie Lesch
LRLisa Rohrbacher
Lisa Rohrbacher
SKSebastian Kobold
Sebastian Kobold

15 July 2016 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
LGLisa Ann Gerdes
Lisa Ann Gerdes
KHKathrin Held
Kathrin Held
EBEduardo Beltrán
Eduardo Beltrán
CBCarola Berking
Carola Berking
JPJörg C. Prinz
Jörg C. Prinz
RHReinhard Hohlfeld
Reinhard Hohlfeld
We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4‐blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T‐cell type MS. Quantitative next generation sequencing of T‐cell receptor genes revealed distinct oligoclonal CD4+ and CD8+ T‐cell repertoires in the primary melanoma and cerebrospinal fluid. Our results pinpoint the coinhibitory molecule CTLA4 as an immunological checkpoint and therapeutic target in MS. Ann Neurol 2016;80:294–300

23 February 2024 in Science Immunology
Verified
Journal Article
Closed access
CWChristine Wolf
Christine Wolf
ELEe Lyn Lim
Ee Lyn Lim
MMMohammad Mokhtari
Mohammad Mokhtari
BKBarbara Kind
Barbara Kind
AOAlexandru Odainic
Alexandru Odainic
MLMin Ae Lee-Kirsch
Min Ae Lee-Kirsch
UNC93B1 is critical for trafficking and function of nucleic acid–sensing Toll-like receptors (TLRs) TLR3, TLR7, TLR8, and TLR9, which are essential for antiviral immunity. Overactive TLR7 signaling induced by recognition of self–nucleic acids has been implicated in systemic lupus erythematosus (SLE). Here, we report UNC93B1 variants (E92G and R336L) in four patients with early-onset SLE. Patient cells or mouse macrophages carrying the UNC93B1 variants produced high amounts of TNF-α and IL-6 and upon stimulation with TLR7/TLR8 agonist, but not with TLR3 or TLR9 agonists. E92G causes UNC93B1 protein instability and reduced interaction with TLR7, leading to selective TLR7 hyperactivation with constitutive type I IFN signaling. Thus, UNC93B1 regulates TLR subtype–specific mechanisms of ligand recognition. Our findings establish a pivotal role for UNC93B1 in TLR7-dependent autoimmunity and highlight the therapeutic potential of targeting TLR7 in SLE.